Latest & greatest articles for warfarin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on warfarin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on warfarin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for warfarin

121. Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation Full Text available with Trip Pro

Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation Edoxaban is an oral, once-daily factor Xa inhibitor that is non-inferior to well-managed warfarin in patients with atrial fibrillation (AF) for the prevention of stroke and systemic embolic events (SEEs). We examined the efficacy and safety of edoxaban vs. warfarin in patients who were vitamin K antagonist (VKA) naive or experienced.ENGAGE AF-TIMI 48 randomized 21 105 patients with AF (...) at moderate-to-high risk of stroke to once-daily edoxaban vs. warfarin. Subjects were followed for a median of 2.8 years. The primary efficacy endpoint was stroke or SEE. As a pre-specified subgroup, we analysed outcomes for those with or without prior VKA experience (>60 consecutive days). Higher-dose edoxaban significantly reduced the risk of stroke or SEE in patients who were VKA naive [hazard ratio (HR) 0.71, 95% confidence interval (CI) 0.56-0.90] and was similar to warfarin in the VKA experienced

2015 EvidenceUpdates Controlled trial quality: predicted high

122. Warfarin: Point-of-Care INR Monitoring

Warfarin: Point-of-Care INR Monitoring © 2015 Thrombosis Canada Page 1 of 3 WARFARIN: POINT-OF-CARE INR MONITORING OBJECTIVE: To provide an overview of point-of-care (POC) international normalized ratio (INR) monitoring. BACKGROUND: A POC device is a small portable instrument that measures clotting time from a fingerstick blood sample. Most POC devices report the result as an INR. POC INR devices vary in their ease of use due to: differences in blood sample volume required, the technique (...) of application of the blood sample to the meter, the need for external quality control testing, refrigeration of test strips, and meter portability. HOW ARE POC DEVICES USED? For both adults and children, use of a POC INR device provides a simple and convenient way to manage warfarin anticoagulation in both the office / clinic setting and at home. The POC INR device requires a drop of blood in order to produce an INR result within one minute. This enables timely warfarin dose adjustments and allows prompt

2015 Thrombosis Interest Group of Canada

123. Warfarin: Management of Out-of-Range INRs

Warfarin: Management of Out-of-Range INRs © 2015 Thrombosis Canada Page 1 of 6 WARFARIN: MANAGEMENT OF OUT-OF-RANGE INRS OBJECTIVE: To provide practical strategies supported by the best available evidence for managing out-of- range international normalized ratios (INRs) for patients on long-term warfarin therapy. BACKGROUND: ? Warfarin can be challenging to manage due to its narrow therapeutic range, variable dose- response among different patients and common interactions with drugs, diet (...) and other factors. ? In patients who are taking warfarin, thromboembolic events and bleeding are strongly related to the time in therapeutic range (TTR). This is the proportion of treatment time that the INR is within the target therapeutic range (typically 2.0 to 3.0). ? Clinicians may underdose warfarin due to a perceived greater risk of harm from bleeding associated with supratherapeutic INR values. However, subtherapeutic anticoagulation has been shown to increase the frequency and severity

2015 Thrombosis Interest Group of Canada

124. Warfarin: Common Causes and Management Strategies for High INRs

Warfarin: Common Causes and Management Strategies for High INRs © 2015 Thrombosis Canada Page 1 of 3 WARFARIN: COMMON CAUSES AND MANAGEMENT STRATEGIES FOR HIGH INRS OBJECTIVE: To provide a summary of the most common causes of and management strategies for high international normalized ratios (INRs) for patients on long-term warfarin therapy. COMMON CAUSES OF HIGH INRS MANAGEMENT STRATEGIES DRUG INTERACTIONS ? Temporary drug interaction: temporary warfarin hold or dose reduction ? Chronic drug (...) interaction: reduce maintenance dose and increase frequency of INR tests until new stable INR is acheived ? Although many drugs may interact with warfarin, avoidance of either warfarin or the interacting drug is usually not required ALTERED HEALTH STATES ? Fever, acute illness, diarrhea, reduced food intake ? Uncontrolled hyperthyroidism ? CHF exacerbation ? Temporarily reduce the dose and increase the frequency of INR testing until the patient’s health stabilizes MALNUTRITION ? (vitamin K deficiency

2015 Thrombosis Interest Group of Canada

125. The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarin treatment: population based observational study. Full Text available with Trip Pro

The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarin treatment: population based observational study. To determine rates of major bleeding by level of kidney function for older adults with atrial fibrillation starting warfarin.Retrospective cohort study.Community based, using province wide laboratory and administrative data in Alberta, Canada.12,403 adults aged 66 years or more, with atrial fibrillation who started warfarin (...) bleeding (intracranial, upper and lower gastrointestinal, or other).Of 12,403 participants, 45% had an eGFR <60 mL/min/1.73 m(2). Overall, 1443 (11.6%) experienced a major bleeding episode over a median follow-up of 2.1 (interquartile range: 1.0-3.8) years. During the first 30 days of warfarin treatment, unadjusted and adjusted rates of major bleeding were higher at lower eGFR (P for trend <0.001 and 0.001, respectively). Adjusted bleeding rates per 100 person years were 63.4 (95% confidence interval

2015 BMJ

126. Comparison of treatment effect estimates of non-vitamin K antagonist oral anticoagulants versus warfarin in non-valvular atrial fibrillation between observational studies using propensity score methods and randomized controlled trials: a systematic review

Comparison of treatment effect estimates of non-vitamin K antagonist oral anticoagulants versus warfarin in non-valvular atrial fibrillation between observational studies using propensity score methods and randomized controlled trials: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content

2015 PROSPERO

127. Pharmacogenetics-based versus clinical dosing of warfarin: a systematic review and meta-analysis of randomized controlled trials

Pharmacogenetics-based versus clinical dosing of warfarin: a systematic review and meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2015 PROSPERO

128. Effect of CYP2C9, VKORC1, and CYP4F2 on warfarin maintenance dose in children: protocol for systematic review and meta-analysis

Effect of CYP2C9, VKORC1, and CYP4F2 on warfarin maintenance dose in children: protocol for systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2015 PROSPERO

129. New oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease [Cochrane Protocol]

New oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease [Cochrane Protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation

2015 PROSPERO

130. Bleeding events with dabigatran or warfarin in patients with venous thromboembolism (Abstract)

Bleeding events with dabigatran or warfarin in patients with venous thromboembolism Dabigatran was as effective as warfarin for the acute treatment of venous thromboembolism in the RE-COVER and RE-COVER II trials. We compared the incidence of bleeding with dabigatran versus warfarin in pooled data from these studies. The localisation, bleeding severity, and the impact of key factors on the incidence of bleeding, were compared between the dabigatran and warfarin treatment group. Altogether, 2553 (...) patients received dabigatran and 2554 warfarin, each for a mean of 164 days. The incidence of any bleeding event was significantly lower with dabigatran (hazard ratio [HR] 0.70; 95% confidence interval [CI], 0.61-0.79), as was the incidence of the composite of MBEs and clinically relevant non-major bleeding events (HR 0.62; 95% CI, 0.50-0.76). The incidence of major bleeding events (MBEs) was also significantly lower with dabigatran in the double-dummy phase (HR, 0.60; 95%CI, 0.36-0.99

2015 EvidenceUpdates Controlled trial quality: uncertain

131. Cohort study: Risk of warfarin-associated intracerebral haemorrhage after ischaemic stroke is low and unchanged during the 2000s Full Text available with Trip Pro

Cohort study: Risk of warfarin-associated intracerebral haemorrhage after ischaemic stroke is low and unchanged during the 2000s Risk of warfarin-associated intracerebral haemorrhage after ischaemic stroke is low and unchanged during the 2000s | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using (...) your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Risk of warfarin-associated intracerebral haemorrhage after ischaemic stroke is low and unchanged during the 2000s Article Text Aetiology/Harm

2015 Evidence-Based Medicine

132. Cohort study: Vitamin K antagonist-experienced patients with a history of stroke/transient ischaemic attack who switched from warfarin to dabigatran increased their rate of recurrent stroke/transient ischaemic attack compared with those on warfarin

Cohort study: Vitamin K antagonist-experienced patients with a history of stroke/transient ischaemic attack who switched from warfarin to dabigatran increased their rate of recurrent stroke/transient ischaemic attack compared with those on warfarin Vitamin K antagonist-experienced patients with a history of stroke/transient ischaemic attack who switched from warfarin to dabigatran increased their rate of recurrent stroke/transient ischaemic attack compared with those on warfarin | BMJ Evidence (...) OR managers of institutional accounts Username * Password * your user name or password? You are here Vitamin K antagonist-experienced patients with a history of stroke/transient ischaemic attack who switched from warfarin to dabigatran increased their rate of recurrent stroke/transient ischaemic attack compared with those on warfarin Article Text Aetiology/Harm Cohort study Vitamin K antagonist-experienced patients with a history of stroke/transient ischaemic attack who switched from warfarin

2015 Evidence-Based Medicine

133. Randomised control trial: Using the Watchman device to close the left atrial appendage reduces risk of stroke in atrial fibrillation, compared to using warfarin

Randomised control trial: Using the Watchman device to close the left atrial appendage reduces risk of stroke in atrial fibrillation, compared to using warfarin Using the Watchman device to close the left atrial appendage reduces risk of stroke in atrial fibrillation, compared to using warfarin | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about (...) fibrillation, compared to using warfarin Article Text Therapeutics/Prevention Randomised control trial Using the Watchman device to close the left atrial appendage reduces risk of stroke in atrial fibrillation, compared to using warfarin Martin J Swaans , Arash Alipour , Lucas V Boersma Statistics from Altmetric.com Commentary to : Reddy VY , Sievert H , Halperin J , et al .; PROTECT AF Steering Committee and Investigators. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation

2015 Evidence-Based Medicine

134. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. Full Text available with Trip Pro

Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. While effective in preventing stroke in patients with atrial fibrillation (AF), warfarin is limited by a narrow therapeutic profile, a need for lifelong coagulation monitoring, and multiple drug and diet interactions.To determine whether a local strategy of mechanical left atrial appendage (LAA) closure was noninferior to warfarin.PROTECT AF was a multicenter, randomized (2:1), unblinded (...) with the device (n = 463) or warfarin (n = 244; target international normalized ratio, 2-3).A composite efficacy end point including stroke, systemic embolism, and cardiovascular/unexplained death, analyzed by intention-to-treat.At a mean (SD) follow-up of 3.8 (1.7) years (2621 patient-years), there were 39 events among 463 patients (8.4%) in the device group for a primary event rate of 2.3 events per 100 patient-years, compared with 34 events among 244 patients (13.9%) for a primary event rate of 3.8 events

2014 JAMA Controlled trial quality: predicted high

135. In nonvalvular atrial fibrillation, effects of rivaroxaban compared with warfarin did not differ by patient age Full Text available with Trip Pro

In nonvalvular atrial fibrillation, effects of rivaroxaban compared with warfarin did not differ by patient age 25402538 2015 04 14 2018 12 02 1539-3704 161 10 2014 Nov 18 Annals of internal medicine Ann. Intern. Med. ACP Journal Club: in nonvalvular atrial fibrillation, effects of rivaroxaban compared with warfarin did not differ by patient age. JC5 10.7326/0003-4819-161-10-201411180-02005 Rondina Matthew M eng K23 HL092161 HL NHLBI NIH HHS United States R01 AG048022 AG NIA NIH HHS United (...) States R01 HL126547 HL NHLBI NIH HHS United States R03 AG040631 AG NIA NIH HHS United States Journal Article Comment United States Ann Intern Med 0372351 0003-4819 0 Factor Xa Inhibitors 0 Morpholines 0 Thiophenes 12001-79-5 Vitamin K 5Q7ZVV76EI Warfarin AIM IM Circulation. 2014 Jul 8;130(2):138-46 24895454 Atrial Fibrillation drug therapy Embolism prevention & control Factor Xa Inhibitors Female Humans Male Morpholines administration & dosage Stroke prevention & control Thiophenes administration

2014 Annals of Internal Medicine

136. Vitamin K for improved anticoagulation control in patients receiving warfarin. Full Text available with Trip Pro

Vitamin K for improved anticoagulation control in patients receiving warfarin. Effective use of warfarin involves keeping the international normalised ratio (INR) within a relatively narrow therapeutic range. However, patients respond widely to their dose of warfarin. Overcoagulation can lead to an increased risk of excessive bleeding, while undercoagulation can lead to increased clot formation. There is some evidence that patients with a variable response to warfarin may benefit from (...) literature and ongoing studies.Randomised controlled trials comparing the addition of vitamin K versus placebo in patients initiating warfarin or already taking warfarin.Two review authors independently selected and extracted data from included studies. When disagreement arose, a third author helped reached a consensus. We also assessed risk of bias.We identified two studies with a total of 100 participants for inclusion in the review. We found the overall risk of bias to be unclear in a number

2014 Cochrane

137. An alternative to warfarin for patients with PE

An alternative to warfarin for patients with PE An alternative to warfarin for patients with PE Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics An alternative to warfarin for patients with PE View/ Open Date 2012-12 Format Metadata Abstract Consider treating patients with acute pulmonary embolism (PE) with rivaroxaban (...) , a factor Xa inhibitor; it works as well as low-molecular-weight heparin (LMWH) followed by warfarin, but may cause fewer major bleeds. Stength of recommendation: B: Based on a single, nonblinded randomized controlled trial. URI Part of Citation Journal of Family Practice, 61(12) 2012: 751-752. Rights OpenAccess. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License. Collections hosted by hosted by

2014 PURLS

138. Factor Xa Inhibitors vs Warfarin for Preventing Stroke and Thromboembolism in Patients With Atrial Fibrillation. (Abstract)

Factor Xa Inhibitors vs Warfarin for Preventing Stroke and Thromboembolism in Patients With Atrial Fibrillation. Is treatment with factor Xa inhibitors associated with better efficacy and safety compared with the vitamin K antagonist warfarin for preventing strokes or other systemic embolic events in patients with atrial fibrillation?Compared with warfarin, factor Xa inhibitors are associated with a lower risk of stroke and other systemic embolic events in patients with atrial fibrillation (...) . Factor Xa inhibitors were associated with lower rates of intracranial hemorrhage and mortality compared with warfarin. Factor Xa inhibitors were associated with a reduction in major bleeding events, but there was heterogeneity between the included studies, and the reduction was not statistically significant in a prespecified sensitivity analysis.

2014 JAMA

139. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. (Abstract)

Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Four new oral anticoagulants compare favourably with warfarin for stroke prevention in patients with atrial fibrillation; however, the balance between efficacy and safety in subgroups needs better definition. We aimed to assess the relative benefit of new oral anticoagulants in key subgroups, and the effects on important secondary outcomes.We (...) searched Medline from Jan 1, 2009, to Nov 19, 2013, limiting searches to phase 3, randomised trials of patients with atrial fibrillation who were randomised to receive new oral anticoagulants or warfarin, and trials in which both efficacy and safety outcomes were reported. We did a prespecified meta-analysis of all 71,683 participants included in the RE-LY, ROCKET AF, ARISTOTLE, and ENGAGE AF-TIMI 48 trials. The main outcomes were stroke and systemic embolic events, ischaemic stroke, haemorrhagic

2014 Lancet

140. Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation. Full Text available with Trip Pro

Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation. Conflicting evidence exists regarding the association between warfarin treatment, death, and ischemic stroke incidence in patients with advanced chronic kidney disease (CKD) and atrial fibrillation.To study outcomes associated with warfarin treatment in relation to kidney function among patients with established cardiovascular disease and atrial fibrillation.Observational (...) , prospective, multicenter cohort study from the Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART) registry (2003-2010), which includes all Swedish hospitals that provide care for acute cardiac diseases. Participants included consecutive survivors of an acute myocardial infarction (MI) with atrial fibrillation and known serum creatinine (N = 24,317), including 21.8% who were prescribed warfarin at discharge

2014 JAMA